Polynovo share price surges after FY25 results, but can it overcome its -37% slide?

What led to Polynovo’s double-digit stock rally—and is it more than just a technical bounce?

Polynovo Ltd (ASX: PNV) saw its share price surge by 11.79% to AUD 1.47 on September 2, 2025, marking one of its strongest single-day gains in recent months. This move, backed by trading volume of over 4.5 million shares, comes as a notable shift following the stock’s year-long decline of more than 37%. While the rally is certainly encouraging for shareholders, the bigger question is whether this performance signals a long-term recovery or simply a short-term sentiment bounce.

At the core of this rally is investor reaction to Polynovo’s recently announced FY25 results, which included robust commercial sales growth, operational leverage gains, positive cash flow, and renewed clinical momentum. With a market capitalization of AUD 1.02 billion and a price-to-earnings ratio of 77.37, the Australian regenerative medicine company remains richly valued, but its growth engine may be showing signs of catching up with expectations.

How did Polynovo perform financially in FY25—and what are the key growth indicators?

Polynovo reported a strong financial performance for the year ended June 30, 2025. Total revenue climbed to AUD 129.2 million, representing a 23.3% increase compared to FY24. Commercial sales, driven by the company’s flagship NovoSorb product range, rose by 28.9% year-over-year to AUD 118.6 million.

Net profit after tax surged to AUD 13.2 million, up 149% from AUD 5.3 million in FY24. EBITDA (a non-IFRS measure) stood at AUD 11.2 million, reflecting a 211% increase. Importantly, this was achieved while operating expenses rose by only 19.4%, indicating strong operational leverage. While revenue from the U.S. government’s BARDA program declined 22.8% to AUD 8.6 million due to the nearing completion of the pivotal trial, the commercial side of the business more than offset this decline.

Polynovo’s results also revealed a shift to positive operating cash flow, with AUD 15.6 million generated in the second half of FY25, reversing an outflow of AUD 12.5 million in the first half. Total operating cash flow for the full year stood at AUD 3.1 million, and the company closed the year with AUD 33.5 million in cash and equivalents.

The manufacturing capacity expansion is nearing completion, with AUD 8.5 million in remaining capital expenditure to be paid in FY26. Management indicated that capex beyond FY26 would be minimal and incidental, further supporting free cash flow potential in the near term.

What drove NovoSorb’s global momentum—and how are international markets contributing to revenue?

NovoSorb’s performance was pivotal in driving Polynovo’s FY25 revenue gains. In the United States, commercial product sales reached AUD 88.4 million, a 28.7% increase over FY24. This growth was supported by 243 new hospital customer accounts, a 58.2% rise in order volume, and a 43.3% increase in units sold. NovoSorb MTX, in particular, generated AUD 6.7 million in FY25 sales following the full launch of the 6 mm variant, which expanded clinical applicability.

The company’s field presence in the U.S. remains strong, with 130 U.S.-based employees, of which 95 operate in field roles. Sales growth has been aided by expanding relationships with Group Purchasing Organizations (GPOs), Integrated Delivery Networks (IDNs), and Federal contracts, enhancing reach into both public and private health systems.

Outside of the U.S., the Rest of World (ROW) markets contributed AUD 30.3 million in product sales, up 29.6% from AUD 23.4 million in FY24. Significant growth was observed in Canada (up 48.5% to AUD 1.9 million), France (up 378.8% to AUD 0.7 million), Turkey (up 36.7% to AUD 1.9 million), and the United Kingdom (up 51.9% to AUD 7.5 million). Notably, initial NovoSorb BTM sales were recorded in new markets including Malaysia, Czech Republic, Malta, Portugal, and Peru, with each of these regions already generating recurring orders.

Polynovo also reported significant expansion in India, where revenue grew by 80.8% and unit volumes rose by 149%. The company won 37 tenders in India and also expanded its footprint into Bangladesh and Nepal. A commercial presence in Hong Kong was expanded into Macau, reflecting the company’s strategic effort to turn regulatory approvals into recurring sales.

What strategic developments are underway—and how might they influence medium-term growth?

Polynovo’s FY25 presentation outlined several strategic initiatives that could shape its medium-term trajectory. A strategic review of the product development roadmap is underway, aiming to align resources with market needs, reimbursement opportunities, and clinical feedback. This review includes the development of both larger and smaller NovoSorb sizes, as well as antimicrobial options now entering preclinical testing.

Importantly, the company completed its 3-month data review of all participants in the BARDA pivotal trial. The optimal strategy for FDA Pre-Market Approval (PMA) submission has been confirmed: the company intends to file after the 12-month data follow-up. A successful PMA could significantly expand access to U.S. federal procurement programs and strengthen the company’s reimbursement position in trauma and burn care.

Polynovo is also advancing a surgical mesh product, with early preclinical animal studies showing positive results when compared to leading synthetic alternatives. These pipeline additions reflect the company’s push to diversify beyond skin substitutes and into broader surgical and regenerative categories.

Leadership changes are also in focus. A new CEO has been appointed to guide the company through its next phase of growth, alongside a refreshed board of directors. This leadership overhaul suggests a pivot toward more commercially aggressive execution and potentially even inorganic growth.

What do valuation metrics and ASX ranking reveal about how Polynovo is positioned in its peer group?

Polynovo’s current P/E ratio of 77.37 indicates that the market continues to price in significant future growth. However, such a valuation also implies vulnerability to any execution missteps or regulatory setbacks. The company does not currently pay a dividend, and its return on capital is still modest compared to peers.

In terms of peer rankings, Polynovo placed 19th out of 232 healthcare companies on the ASX, and 352nd among 2,297 listed companies overall. While not yet a top-tier stock by market-wide standards, its sector-specific positioning suggests that investors are starting to distinguish Polynovo from earlier-stage or less commercially proven biotech peers.

While institutional interest remains measured, this kind of rebound—and the strong results backing it—could spur upgrades or attract new positions, particularly if PMA approval comes through on schedule and commercial momentum sustains into FY26.

What are the key risks facing Polynovo even as growth accelerates post-FY25?

Despite the positive financial and operational signals, Polynovo is not without risks. The most pressing is execution risk around its planned PMA submission. Delays or additional data requirements from the FDA could disrupt timelines or increase cash burn. Although the company is now cash-flow positive, capital efficiency will remain a critical focus, especially given lingering volatility in healthcare funding cycles.

Another potential headwind is the competitive landscape in regenerative medicine. Companies with synthetic skin substitutes and wound healing platforms are also gaining ground. Polynovo must continue to differentiate based on clinical data, surgeon adoption, and reimbursement alignment.

There’s also the broader concern around valuation. At a P/E above 77, the market expects more than just growth—it expects category leadership and consistency. Any revenue miss, margin contraction, or reimbursement delays could quickly reintroduce downside volatility.

Polynovo’s turnaround is real—but it’s only the beginning of what it needs to prove

Polynovo’s double-digit share price rally following the FY25 earnings release marks an inflection point in sentiment. For a company that has spent much of the past year in decline, the return to profitability, global expansion, and strong NovoSorb sales provide compelling reasons for optimism. However, sustaining this momentum will require continued clinical execution, market penetration, and successful navigation of the FDA PMA pathway.

For long-term holders still sitting on paper losses, the worst may be behind them. But for Polynovo to evolve from a high-potential story to a core healthcare holding, it must now deliver consistent quarters of profitable growth and product diversification. FY25 may have been the turning point—but the proving ground lies ahead.